Overview
The company's platforms—Allo-Glue™, A-Kine®, and multimodal cell engagers—work by connecting proteins on and within cells to target cancer through the body's natural defense mechanisms. Orionis focuses on precision targeting to harness immune signaling while minimizing off-target effects.
Key people
In the news
- Bringing both Biotech and the Tech industry together at the Tech x Bio night in Ghent was a smart move. It was interesting to see talks from argenx and Orionis Biosciences outside the "normal scientific conference" setting that I am used to. Vice-versa it was also inspiring to see the tech-talks from Aikido Security and TechWolf in their kind of "natural Wintercircus" habitat. It's now the second time that I see Jeroen Van Hautte 🐺 showing live Claude Code sessions and I love the style 😁 The ambition to scale globally from day
- About two years ago, when working at VIB, I started lobbying/pushing to get more biotech & life sciences on the agenda of Wintercircus Ghent. So full circle on October 27, as VIB and Wintercircus Ghent are filling up the building with +400 tech and biotech people for FTI Tech x Bio Night - so this one is really close to my heart. Amongst others: Karen Massey ( argenx ), Roeland Delrue ( Aikido Security ), Riccardo Sabatini ( Orionis Biosciences ) and Jeroen Van Hautte 🐺 ( TechWolf ) will be sharing the stage and discuss
- We’re pleased to announce that we’ve entered into a strategic, multi-year collaboration with Novartis to discover and develop next-generation molecular glue medicines across multiple therapeutic areas. The collaboration builds on an existing relationship between the two companies and will leverage Orionis’ Allo-Glue™ platform and AI-driven discovery engine to accelerate target-ligase profiling and molecular glue discovery and optimization. As part of this collaboration, Orionis will receive a $40M upfront payment and is
Something wrong or missing? Send an update. Fixed within 24 hours.